Wellness
Women’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage

Women’s HealthX has announced its lineup of healthcare trailblazers speaking on Chronic Disease Management, alongside other specialisations including Fertility, Sexual Health, Maternity, Menopause and Cognitive Health, taking a holistic approach to women’s health.
It will bring together 750+ leaders across pharma, health systems, and innovation to address one of the most urgent and underexamined challenges in healthcare; the sex difference gap in data and evidence.
Since cardiovascular disease remains the leading cause of death among women globally, and autoimmune and neurological conditions affect women at significantly higher rates, Women’s HealthX will home in on chronic disease management with 17+ sessions spotlighting case studies and lessons learned.
The Chronic Disease Management Stage at Women’s HealthX responds directly to this gap, convening senior decision makers and innovators to explore how sex specific science, digital health, and new care models can reshape outcomes for women.
Attending pharma & healthcare organisations include:
- Tracy Sims, Executive Director, Cardiometabolic Health, Eli Lilly
- Adrian Kielhorn, Senior Director, Global Head HEOR Neurology, Alexion Pharmaceuticals
- Lauren Powell, Head of Health Equity and Clinical Innovation, Biogen
- Amy Kao, SVP, Head of Neuroscience and Immunology Research, EMD Serono
- Stella Vnook, Executive Chair and CEO, Kaida Biopharma
- Amanda Borsky, Director, Clinical Research, Northwell Health
- Lacey McIntosh, Division Chief, Oncologic and Molecular Imaging, UMass Memorial Medical Center
- Nicole Turck, Vice President Operations, Women’s Health, Corewell Health
- Mette Dyhrberg, CEO, Autoimmune Registry
- Lyn Agostinelli, Principal Consultant, Halloran Consulting Group
Sessions addressing the real gaps in women’s chronic care
The agenda features a series of high impact sessions tackling the structural and scientific gaps in women’s health:
- Improving outcomes in obesity through evidence based person centered care: Eli Lilly
- Tackling sex based health inequities by breaking down barriers and bias: Alexion Pharmaceuticals
- Close the health equity gap in women’s health by improving how autoimmune diseases are diagnosed, treated and managed: Autoimmune Registry
- How a GYN only care model is driving faster access to gynecological care: Corewell Health
- Transforming early detection in ovarian cancer: new pathways to accuracy, safety, and better outcomes: UMass Memorial Medical Center
Panel discussions include:
- Why chronic disease looks different in women and why health systems haven’t adapted: Biogen, Kaida Biopharma, EMD Serono
- How can we better engage with our customers: Northwell Health, Halloran Consulting Group
Health equity starts here. REGISTER YOUR PLACE
Why This Matters Now
Women’s HealthX positions chronic disease not just as a clinical challenge, but as a critical frontier for innovation, investment, and system redesign.
From AI powered monitoring and digital therapeutics to real world data and integrated care pathways, the stage highlights where meaningful progress is already being made and where the biggest opportunities lie.
For the FemTech ecosystem, this represents a pivotal moment: aligning technology, clinical insight, and commercial strategy to finally close the long standing data and care gaps in women’s health.
About Women’s HealthX
Women’s HealthX is where the transformation of women’s health begins at its true foundation: data, science, and evidence.
It’s the leading event dedicated to closing the sex difference data gap and accelerating breakthroughs through science driven, real world case studies.
Taking place on December 3 to 4, 2026 in Boston, USA, the exhibition will bring together more than 750 healthcare leaders, including clinicians, payers, employers, investors, and policymakers.
Seven different stages with 150+ expert speakers taking an holistic approach to women’s health. From fertility, maternity, sexual health, cognitive health, menopause and chronic disease, we address care at every stage of a woman’s life.
News
Ovum secures US$4m in seed funding

Women’s health startup Ovum has raised US$4m in seed funding to develop its AI health journal and expand research using women’s health data.
The round valued the Melbourne startup at US$18m.
Ovum plans to use the funding to develop its artificial intelligence technology and longitudinal datasets, which track health information over time to reveal changes and patterns.
The AI captures symptoms, lifestyle factors, biometric measurements, reproductive health stages, medication, appointments and medical reports.
It uses this information to identify health patterns and create summaries and questions for medical appointments.
Ovum previously raised US$1.7m in pre-seed funding in February 2025 before launching its health journal app in August that year.
Since then, the company says the app has grown by 30 per cent month on month and recorded more than 20,000 downloads.
It has captured 57,000 health data insights and hosted more than 107,000 AI health conversations involving women aged between 15 and 84.
Founder Dr Ariella Heffernan-Marks developed the idea while she was a third-year medical student experiencing chronic migraines and was told that her pain was caused by anxiety.
The company describes the resulting women’s health journal as combining technology and clinical research to make health information more actionable and equitable for women.
Heffernan-Marks said: “I’ve sat on both sides of the desk, as a patient and as a doctor, and that’s why this mission matters so much to me.
“For too long, women have had to navigate healthcare systems that were not designed around their lived experiences or backed by sufficient female health data. Ovum exists to help women better understand their bodies, advocate for themselves with confidence, and contribute to research that improves care for future generations.”
Private health insurer Medibank is an Ovum partner, alongside Fernwood Fitness, Sweat and Menopause Friendly Australia.
Australian Red Cross Lifeblood is also involved in a pilot examining productivity losses caused by women reducing their working hours or leaving employment for health reasons.
Earlier in 2026, Ovum launched clinical trials with St George Hospital and the Royal Hospital for Women to assess AI as a preventative health tool for women.
The research is examining how women currently manage their health, which digital tools they use and whether AI could support health confidence, self-advocacy and continuity of care.
Continuity of care means receiving connected and consistent support across different appointments, healthcare professionals and services.
The funding round was led by Admiralty Capital Group, with participation from Antler, Giant Leap, Aviron Investments, Foggy Valley Aotearoa, Brisbane Angels and Think & Grow.
Existing investor LaunchVic, which is due to merge with Breakthrough Victoria, also participated through its Alice Anderson Fund, which focuses on female founders.
Amanda Andriano, founding partner at Admiralty Capital Group, said the gender health gap was a problem that should not be tolerated.
She said: “Ovum combines mission, market timing and technical capability with an exceptional founder uniquely positioned to lead this movement, and we believe that creates the foundation for a company of global significance.”
Ageing
Strength training may lower heart disease risk in women, study suggests

Women who do strength training may have a lower risk of major cardiovascular disease, particularly alongside aerobic activity, a study suggests.
Cardiovascular disease is the leading cause of death worldwide. Aerobic activities such as brisk walking, jogging, cycling and swimming are already established ways to help reduce the risk.
Strength or resistance training, also known as RT, is less established as a prevention strategy. It makes muscles work against a force and can involve body weight, free weights, resistance bands or machines.
Current US guidelines recommend at least two days of strength training and 150 minutes of moderate-to-vigorous aerobic activity each week.
They also recommend limiting sedentary behaviour, including prolonged television viewing, which is considered an independent risk factor for cardiovascular disease.
Dr Tianyue Zhang, lead study author and scientist in the department of nutrition at the Harvard T.H. Chan School of Public Health, said: “Despite its established health benefits, RT is often overlooked as a prevention strategy for CVD, and its impact on CVD risk, especially in middle-aged and older women, remains understudied.
“A key question is, how much does it add beyond aerobic activity alone?”
Researchers analysed data from 117,025 women participating in the Nurses’ Health Study and Nurses’ Health Study II.
The two groups had average starting ages of 66.8 and 48.1 years respectively.
The women reported their resistance training every four years, with exercises involving the arms and legs recorded separately.
Time spent watching television was used as the main measure of sedentary behaviour.
The researchers examined exercise and television-viewing habits alongside the incidence of major cardiovascular disease.
Major cardiovascular events included fatal or non-fatal heart attacks, strokes, coronary artery bypass surgery and percutaneous coronary intervention.
Coronary artery bypass surgery redirects blood around narrowed or blocked heart arteries. Percutaneous coronary intervention uses a small balloon, often followed by a stent, to open a narrowed artery.
Higher levels of strength training were associated with a lower risk of major cardiovascular disease, particularly heart attacks.
No statistically significant link with stroke was found when resistance exercise was considered separately.
Women completing at least two hours of strength training a week had a 20 per cent lower risk of major cardiovascular disease and a 44 per cent lower risk of heart attack than those doing none.
Each additional hour a week was associated with a five per cent lower risk of major cardiovascular disease and a 14 per cent lower risk of heart attack.
The associations weakened somewhat after researchers accounted for body mass index and conditions including diabetes, high blood pressure and high cholesterol, but remained clear.
Body mass index, or BMI, compares weight with height and is commonly used to assess whether someone is within a healthy weight range.
Strength training was also linked to additional benefits among women who did aerobic activity.
Women completing at least two hours of strength training and 150 minutes of aerobic activity each week had a 45 per cent lower risk of heart attack than those reporting no physical activity.
Women who met recommendations for strength training, aerobic activity and reduced television viewing had the lowest risks of major cardiovascular disease, heart attack and stroke compared with those who met some or none of the recommendations.
Zhang said: “These findings suggest that, within an already active population, RT is associated with additional reductions in CVD risk above and beyond overall aerobic activity.
“Alongside aerobic activity and reductions in sedentary behaviour, RT may be an important component of public health strategies for cardiovascular prevention in women.”
The study relied on participants reporting their own resistance training, meaning the data may not always have been precise.
Researchers also noted the possible influence of unmeasured factors and the limited diversity of participants.
They were unable to fully separate the effects of the type of resistance training performed from the overall amount completed.
Dr Harlan M. Krumholz, professor at Yale School of Medicine, said: “We have long encouraged resistance training, and this study provides strong evidence to reinforce that message.
“It should be included in a well-rounded health routine to support function and longevity.”
Pregnancy
Women with pre-eclampsia at increased risk of chronic kidney disease, study finds

Women who develop pre-eclampsia face a higher risk of chronic kidney disease and high blood pressure later in life, new research suggests.
The amount of protein found in the urine during pregnancy may help identify those at greatest risk of developing long-term health problems.
Pre-eclampsia usually involves high blood pressure and increased protein in the urine. Some women also experience severe headaches and changes to their vision.
The condition cannot be treated during pregnancy and, in some cases, labour must be induced early to protect both the woman and baby.
The study found that the condition may be linked to longer-term health problems.
Anne Høy Seemann Vestergaard, a medical doctor and PhD at the department of clinical medicine at Aarhus University, said: “What we can see is a clear association between pre-eclampsia and the development of high blood pressure, chronic kidney disease and cardiovascular disease later in life.”
The researchers found that the amount of protein passed in the urine during pregnancy was linked to the risk of developing chronic conditions after giving birth.
Protein in the urine can indicate that the kidneys are not filtering blood normally.
Vestergaard said: “The most surprising finding was how clearly the amount of protein in the urine during pre-eclampsia was linked to the risk of later high blood pressure and chronic kidney disease. Women with moderate to severe protein excretion had a higher risk of both conditions compared with women with low or no protein excretion.”
Among women with pre-eclampsia and moderate to severe levels of protein in the urine, around one in 20 developed chronic kidney disease within 10 years and around one in six developed high blood pressure.
Most women in the study did not develop long-term complications, but the researchers said the increased risk should still be taken seriously because the potential effects can be severe.
Vestergaard said: “At first glance, this may sound like a low number, but it represents a markedly increased risk when the groups are compared. In the group with pre-eclampsia and high levels of protein in the urine, around 1 in 20 women developed chronic kidney disease within ten years, including early stages of the disease, compared with around 1 in 100 in the group with lower or no protein excretion.”
She added: “That is a considerable number in light of the fact that chronic kidney disease is a potentially serious condition that can progress to kidney failure if isn’t diagnosed early.”
The findings suggest women who experience pre-eclampsia may benefit from more systematic monitoring after pregnancy.
Vestergaard said: “Our study suggests that these women may benefit from monitoring of blood pressure and kidney function after pregnancy.”
Menopause4 weeks agoPerimenopause misinformation ‘putting women at risk’
Entrepreneur4 weeks agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
Insight3 weeks agoBritish women among angriest in Europe, health survey reveals
News4 weeks agoWomen still being failed when they reach menopause, experts say
Hormonal health4 weeks agoSweden eyes domestic production of oestrogen patches amid menopause treatment shortage
Hormonal health2 weeks agoApple Health adds menopause and perimenopause tracking
News2 weeks agoFemtech World Awards 2026: Winners revealed
News4 weeks agoThree menopause innovators shortlisted for Femtech World Award















1 Comment